Relaxant effects of sildenafil on the human isolated bladder neck

DOI: 10.1016/j.urology.2008.06.060
Urology, 2009, 73, 427-30.

#	Paper	IF	Citations
26	Current world literature. *Current Opinion in Urology*, **2010**, 20, 98-103	2.8	
25	[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article]. *Progres En Urologie*, **2010**, 20, 616-26	0.9	2
24	Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. *Urology*, **2010**, 75, 1452-8	1.6	51
23	Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. *Urological Science*, **2010**, 21, 2-7	0.3	
22	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. *British Journal of Clinical Pharmacology*, **2011**, 72, 197-204	3.8	43
21	Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. *International Journal of Clinical Practice*, **2011**, 65, 1005-13	2.9	34
20	Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. *European Urology*, **2011**, 60, 527-35	10.2	42
19	Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. *Neurourology and Urodynamics*, **2011**, 30, 292-301	2.3	162
18	Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. *European Urology*, **2012**, 62, 1174-80	10.2	58
17	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *The Cochrane Library*, **2012**,	5.2	1
16	Les inhibiteurs de la phosphodiestérase de type 5 : une révolution dans le traitement des symptômes du bas appareil urinaire?. *Basic and Clinical Andrology*, **2012**, 22, 80-91	2.8	1
15	Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. *Journal of Urology*, **2013**, 189, 754-61	2.5	50
14	The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. *European Urology*, **2013**, 63, 506-16	10.2	103
13	The role of phosphodiesterases in bladder pathophysiology. *Nature Reviews Urology*, **2013**, 10, 414-24	5.5	22
12	Nitric Oxide Synthase is Necessary for Normal Urogenital Development. **2013**, 2, 108		1
11	A comprehensive review of urologic complications in patients with diabetes. *SpringerPlus*, **2014**, 3, 549		38
10	Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial--treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. *Urology*, **2014**, 84, 51-6	1.6	26

9	Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens. *Canadian Urological Association Journal*, **2015**, 9, 414-9	1.2	4
8	Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. *Therapeutic Advances in Urology*, **2015**, 7, 249-64	3.2	17
7	Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). *Expert Opinion on Emerging Drugs*, **2015**, 20, 555-70	3.7	21
6	Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study. *Scandinavian Journal of Urology*, **2017**, 51, 33-37	1.6	5
5	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *The Cochrane Library*, **2018**, 11, CD010060	5.2	8
4	Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study. *World Journal of Urology*, **2019**, 37, 867-872	4	12
3	Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats. *International Neurourology Journal*, **2015**, 19, 19-26	2.6	4
2	Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model. *Turkish Journal of Urology*, **2017**, 43, 434-438	1.3	
1	Efficacy of Tadalafil on Ureteral Stent Symptoms: A Randomized Controlled Trial. *Nephro-Urology Monthly*, **2019**, In Press,	0.4	